α-アンチトリプシン欠乏症:市場インサイト、疫学分析、市場予測

◆英語タイトル:Alpha- Antitrypsin Deficiency - Market Insights, Epidemiology and Market Forecast-2023
◆商品コード:DLVE704018
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2017年3月
◆ページ数:92
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2営業日以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名使用)USD4,950 ⇒換算¥524,700見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD9,900 ⇒換算¥1,049,400見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD14,850 ⇒換算¥1,574,100見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

DelveInsight’s “Alpha- Antitrypsin Deficiency – Market Insights, Epidemiology and Market Forecast-2023” Report provides an overview of the disease and global market size of the Alpha- Antitrypsin Deficiency for the 7MM (United States, EU5 (France, Germany, Italy, Spain and UK) and Japan. It also includes global historical and forecasted epidemiological data for the prevalent, diagnosed and treatable cases of Alpha-Antitrypsin Deficiency from 2013-2023.The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope
- Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
- Marketed information including available prescription drugs, its patent and exclusivity details.
- The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2013-2023.
- It also provides Market size of Alpha-Antitrypsin Deficiency for United States, EU5 and Japan from 2013 and forecasted Market size to 2023.

【レポートの目次】

• Report Introduction
• Alpha-Antitrypsin Deficiency Market Overview at a Glance
o Global Market Size of Alpha-Antitrypsin Deficiency in 2015
o Global Market Size of Alpha-Antitrypsin Deficiency in 2023
• Alpha-Antitrypsin Deficiency
o Overview
o Types
o Signs and symptoms
o Pathophysiology
o Risk Factors
o Diagnosis
o Treatment
• Epidemiology of Alpha-Antitrypsin Deficiency in 7MM
o United States
o Europe
o United Kingdom
o France
o Italy
o Germany
o Spain
o Japan
• Treatment Algorithm
• Current Unmet Needs
• Marketed Drugs
• Aralast NP : Shire
o Drug Description
o Mechanism of Action
o Regulatory Milestones
o Advantages & Disadvantages
o Safety and Efficacy of Gemzar
o Product Profile
• Zemaira : CSL Behring
o Drug Description
o Mechanism of Action
o Regulatory Milestones
o Advantages & Disadvantages
o Safety and Efficacy of Alimta
o Product Profile
• Glassia : Kamada
o Drug Description
o Mechanism of Action
o Regulatory Milestones
o Advantages & Disadvantages
o Safety and Efficacy of Platinol
o Product Profile
• Prolastin C : Grifols
o Drug Description
o Mechanism of Action
o Regulatory Milestones
o Advantages & Disadvantages
o Safety and Efficacy of Paraplatin
o Product Profile
• Emerging Therapies
• Alpha-1 antitrypsin deficiency gene therapy : Applied Genetic Technologies
o Regulatory Milestones
o Advantages & Disadvantages
o Clinical Development
o Product Profile
o Clinical Pipeline Activity
o Ongoing Trials Information
o Clinical Trial by Phase
• Global Alpha-Antitrypsin Deficiency: Country-Wise Market Analysis
o Overview on Total Alpha-Antitrypsin Deficiency Market
• Total Market Size of Alpha-Antitrypsin Deficiency for 7 MM in 2013-2023
• United States
o Market Size of Alpha-Antitrypsin Deficiency in United States
• EU5
o Market Size of Alpha-Antitrypsin Deficiency in United Kingdom
o Market Size of Alpha-Antitrypsin Deficiency in Germany
o Market Size of Alpha-Antitrypsin Deficiency in France
o Market Size of Alpha-Antitrypsin Deficiency in Italy
o Market Size of Alpha-Antitrypsin Deficiency in Spain
• Japan
o Market Size of Alpha-Antitrypsin Deficiency in Japan
• Drivers
• Restraints
• Appendix
• Report Methodology
• Consulting Services
• Disclaimer
• About DelveInsight

Table 1: Prevalent Population of Alpha-Antitrypsin Deficiency in United States (2013-2023)
Table 2: Prevalent Population of Alpha-Antitrypsin Deficiency in United Kingdom (2013-2023)
Table 3: Prevalent Population of Alpha-Antitrypsin Deficiency in France (2013-2023)
Table 4: Prevalent Population of Alpha-Antitrypsin Deficiency in Italy (2013-2023)
Table 5: Prevalent Population of Alpha-Antitrypsin Deficiency in Germany (2013-2023)
Table 6: Prevalent Population of Alpha-Antitrypsin Deficiency in Spain (2013-2023)
Table 7: Prevalent Population of Alpha-Antitrypsin Deficiency in Japan (2013-2023)
Table 8: Alpha-1 antitrypsin deficiency gene therapy, Clinical Trials by Zone, 2017
Table 9: Clinical Trials by Recruitment status, 2017
Table 10: Total Market size of Alpha-Antitrypsin Deficiency in USD Million (2013-2023)
Table 11: United States Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)
Table 12: United Kingdom Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)
Table 13: Germany Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)
Table 14: France Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)
Table 15: Italy Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)
Table 16: Spain Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)
Table 17:Japan Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)


Figure 1: Prevalent Population of Alpha-Antitrypsin Deficiency in United States (2013-2023)
Figure 2: Prevalent Population of Alpha-Antitrypsin Deficiency in United Kingdom (2013-2023)
Figure 3: Prevalent Population of Alpha-Antitrypsin Deficiency in France (2013-2023)
Figure 4: Prevalent Population of Alpha-Antitrypsin Deficiency in Italy (2013-2023)
Figure 5: Prevalent Population of Alpha-Antitrypsin Deficiency in Germany (2013-2023)
Figure 6: Prevalent Population of Alpha-Antitrypsin Deficiency in Spain (2013-2023)
Figure 7: Prevalent Population of Alpha-Antitrypsin Deficiency in Japan (2013-2023)
Figure 8: Alpha-1 antitrypsin deficiency gene therapy, Clinical Trials by Zone, 2017
Figure 9: Clinical Trials by Recruitment status, 2017
Figure 10: Total Market size of Alpha-Antitrypsin Deficiency in USD Million (2013-2023)
Figure 11: United States Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)
Figure 12: United Kingdom Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)
Figure 13: Germany Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)
Figure 14: France Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)
Figure 15: Italy Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)
Figure 16: Spain Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)
Figure 17:Japan Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)


【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ α-アンチトリプシン欠乏症:市場インサイト、疫学分析、市場予測(Alpha- Antitrypsin Deficiency - Market Insights, Epidemiology and Market Forecast-2023)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆